DK3795573T3 - Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf - Google Patents

Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf Download PDF

Info

Publication number
DK3795573T3
DK3795573T3 DK20199091.8T DK20199091T DK3795573T3 DK 3795573 T3 DK3795573 T3 DK 3795573T3 DK 20199091 T DK20199091 T DK 20199091T DK 3795573 T3 DK3795573 T3 DK 3795573T3
Authority
DK
Denmark
Prior art keywords
triazolopyrasines
compositions
methods
certain
certain triazolopyrasines
Prior art date
Application number
DK20199091.8T
Other languages
English (en)
Inventor
Wei-Guo Su
Hong Jia
Guangxiu Dai
Original Assignee
Hutchison Medipharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44226181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3795573(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hutchison Medipharma Ltd filed Critical Hutchison Medipharma Ltd
Application granted granted Critical
Publication of DK3795573T3 publication Critical patent/DK3795573T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
DK20199091.8T 2009-12-31 2010-12-30 Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf DK3795573T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009076321 2009-12-31
EP19151824.0A EP3511330B1 (en) 2009-12-31 2010-12-30 Synthetic intermediate useful in the preparation of triazolopyridine c-met inhibitors

Publications (1)

Publication Number Publication Date
DK3795573T3 true DK3795573T3 (da) 2022-09-19

Family

ID=44226181

Family Applications (3)

Application Number Title Priority Date Filing Date
DK19151824.0T DK3511330T3 (da) 2009-12-31 2010-12-30 Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer
DK13198224.1T DK2719699T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, præparater dermed og fremgangsmåder til anvendelse deraf
DK20199091.8T DK3795573T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK19151824.0T DK3511330T3 (da) 2009-12-31 2010-12-30 Syntetisk mellemprodukt, der er anvendeligt til fremstilling af triazolopyridin-c-met-inhibitorer
DK13198224.1T DK2719699T3 (da) 2009-12-31 2010-12-30 Bestemte triazolopyraziner, præparater dermed og fremgangsmåder til anvendelse deraf

Country Status (38)

Country Link
US (7) US8987269B2 (da)
EP (5) EP2719699B1 (da)
JP (5) JP5337313B2 (da)
KR (3) KR101434766B1 (da)
CN (3) CN106117248B (da)
AU (2) AU2010338712B2 (da)
BR (1) BR112012016129B1 (da)
CA (1) CA2785749C (da)
CL (1) CL2012001752A1 (da)
CO (1) CO6612235A2 (da)
CU (1) CU24167B1 (da)
CY (2) CY1118250T1 (da)
DK (3) DK3511330T3 (da)
DO (1) DOP2012000188A (da)
EA (2) EA030141B1 (da)
EC (1) ECSP12012011A (da)
ES (4) ES2726152T3 (da)
GT (1) GT201200220A (da)
HK (2) HK1194071A1 (da)
HR (3) HRP20221090T1 (da)
HU (3) HUE025504T2 (da)
IL (2) IL220433B (da)
LT (1) LT3795573T (da)
ME (1) ME02211B (da)
MX (1) MX336996B (da)
MY (1) MY179933A (da)
NI (1) NI201200118A (da)
NZ (1) NZ601128A (da)
PE (3) PE20211094A1 (da)
PL (3) PL3511330T3 (da)
PT (3) PT3795573T (da)
RS (3) RS61281B1 (da)
SG (1) SG181781A1 (da)
SI (2) SI3511330T1 (da)
SM (1) SMT201500213B (da)
UA (1) UA107822C2 (da)
WO (1) WO2011079804A1 (da)
ZA (1) ZA201205730B (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02211B (me) 2009-12-31 2016-02-20 Hutchison Medipharma Ltd Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
CN103068824B (zh) * 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
CN102516046A (zh) * 2011-11-22 2012-06-27 太仓市运通化工厂 一种2-溴丙醛的合成方法
MX359888B (es) * 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
CA2776178A1 (en) 2012-04-05 2013-10-05 Hydro-Quebec Ionic compounds
KR101745741B1 (ko) 2012-08-13 2017-06-12 한국화학연구원 신규한 트리아졸로 피라진 유도체 및 그의 용도
BR112015016580A2 (pt) * 2013-01-11 2017-07-11 Fujifilm Corp composto heterocíclico contendo nitrogênio ou sal deste
ES2642201T3 (es) 2013-03-06 2017-11-15 Astrazeneca Ab Inhibidores de quinazolina de formas mutantes de activación del receptor del factor de crecimiento epidérmico
CN103265468A (zh) * 2013-06-17 2013-08-28 连云港盛和生物科技有限公司 一种2,4-二甲基-3-吡咯甲酸乙酯的合成方法
EP2818471A1 (en) * 2013-06-27 2014-12-31 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Nitrogen bicyclic compounds as inhibitors for Scyl1 and Grk5
BR112016006444B1 (pt) * 2013-09-30 2021-01-19 Korea Research Institute Of Chemical Technology derivado de triazolopirazina e composições farmacêuticas compreendendo o mesmo
EP3309160A1 (en) * 2013-12-26 2018-04-18 Ignyta, Inc. Pyrazolo[1,5-a]pyridine derivatives and methods of their use
JP2016048495A (ja) * 2014-08-28 2016-04-07 京セラ株式会社 携帯端末、レコメンドプログラム、レコメンドシステムおよびレコメンド方法
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017114453A1 (zh) * 2015-12-31 2017-07-06 上海医药集团股份有限公司 喹啉类化合物及其盐的晶型、制备方法、组合物与应用
GB201616116D0 (en) 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR20180092096A (ko) 2017-02-08 2018-08-17 에이비온 주식회사 트리아졸로 피라진 유도체의 신규한 다형체 및 이의 제조 방법
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
CN108570053A (zh) * 2017-03-13 2018-09-25 中国科学院上海药物研究所 五元并六元杂环化合物、制备方法、中间体、组合和应用
KR101924801B1 (ko) 2017-08-16 2018-12-04 한국원자력의학원 트리아졸로피리딘계 유도체를 유효성분으로 함유하는 암 예방 또는 치료용 조성물
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
JP2022500494A (ja) 2018-09-11 2022-01-04 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag ３−［（１Ｓ）−１−イミダゾ［１，２−ａ］ピリジン−６−イルエチル］−５−（１−メチルピラゾール−４−イル）トリアゾロ［４，５−ｂ］ピラジン及びその多形相の改良製造法
BR112021005506A2 (pt) 2018-09-25 2021-06-15 Achillion Pharmaceuticals, Inc. formas mórficas de inibidores de fator complementar d
AU2019373416A1 (en) * 2018-10-30 2021-06-10 Repare Therapeutics Inc. Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors
BR112021011547A2 (pt) 2018-12-14 2021-08-31 Beta Pharma, Inc. Compostos substituídos com organofósforos como inibidores de c-met, e seus usos terapêuticos
KR20220035925A (ko) * 2019-07-22 2022-03-22 리페어 세라퓨틱스 인크. Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체
EP4107166A1 (en) * 2020-02-20 2022-12-28 Achillion Pharmaceuticals, Inc. Heteroaryl compounds for treatment of complement factor d mediated disorders
WO2021229605A1 (en) * 2020-05-14 2021-11-18 Dr. Reddy's Laboratories Limited Process for preparation of savolitinib and its intermediates
US20240026401A1 (en) * 2020-09-28 2024-01-25 Codexis, Inc. Engineered biocatalysts and methods for synthesizing chiral amines
US20240076285A1 (en) * 2020-12-16 2024-03-07 Shankar Venkatraman Compounds and compositions for treating conditions associated with sting activity
JP2024501691A (ja) 2021-01-08 2024-01-15 アビオン インク． トリアゾロピラジン誘導体化合物を有効成分とする薬学的組成物のタブレット錠の製造方法
CN113278019A (zh) * 2021-05-31 2021-08-20 河南偶联生物科技有限公司 一种咪唑并[1,2-a]吡啶类化合物的合成方法
WO2023205722A1 (en) * 2022-04-20 2023-10-26 Engrail Therapeutics, Inc. Gabaa receptor modulator salts, particles, and uses thereof
WO2024008929A1 (en) 2022-07-08 2024-01-11 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors in combination with hgf-receptor inhibitors for the treatment of cancer
CN115611802B (zh) * 2022-12-02 2023-03-14 北京迪泰医药科技有限公司 一种3-乙酰基-2-氯吡啶的合成方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US5977134A (en) * 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP1615931A1 (en) 2003-04-09 2006-01-18 Biogen Idec MA Inc. Triazolopyrazines and methods of making and using the same
US6979505B2 (en) * 2003-06-09 2005-12-27 Utc Fuel Cells, Llc Method and apparatus for removal of contaminants from a hydrogen processor feed stream, as in a fuel cell power plant
US7122548B2 (en) 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7250417B2 (en) * 2003-07-02 2007-07-31 Sugen Inc. Arylmethyl triazolo- and imidazopyrazines as c-Met inhibitors
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
EP1781654A1 (en) 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US20090209577A1 (en) 2004-08-18 2009-08-20 Pfizer Inc. Novel Triazolopyridine Compounds
CN101119996A (zh) * 2005-02-16 2008-02-06 阿斯利康(瑞典)有限公司 化学化合物
KR20070104936A (ko) * 2005-02-16 2007-10-29 아스트라제네카 아베 화합물
NZ568666A (en) * 2005-11-30 2011-09-30 Vertex Pharma [1,2,4]Triazolo[3,4-b][1,3,4]thiadiazole derivative as inhibitors of c-Met
AP3433A (en) 2005-12-21 2015-10-31 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modultors
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
WO2007138472A2 (en) 2006-05-30 2007-12-06 Pfizer Products Inc. Triazolopyridazine derivatives
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) * 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
CA2660836A1 (en) 2006-08-07 2008-02-21 Incyte Corporation Triazolotriazines as kinase inhibitors
CN101796056A (zh) 2006-09-18 2010-08-04 沃泰克斯药物股份有限公司 c-MET的杂环抑制剂及其用途
PL2084162T3 (pl) 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Bicykliczne triazole jako modulatory kinaz białkowych
MX2009004060A (es) * 2006-10-23 2009-06-19 Sgx Pharmaceuticals Inc Moduladores de proteina cinasa de triazolpiridazina.
NO346024B1 (no) 2006-11-22 2022-01-03 Incyte Holdings Corp Imidazotriaziner og imidazopyrimidiner som kinaseinhibitorer
CN101679436A (zh) 2007-04-10 2010-03-24 Sgx药品公司 稠环杂环激酶调节剂
WO2008138842A1 (en) 2007-05-10 2008-11-20 Galapagos N.V. Imidazopyrazines and triazolopyrazine for the treatment of joint degenerative and inflammatory diseases
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
AU2009218459A1 (en) 2008-02-28 2009-09-03 Novartis Ag Imidazo [1,2-B] pyridazine derivatives for the treatment of C-Met tyrosine kinase mediated disease
EP2310389B1 (en) 2008-05-22 2012-01-04 Amgen Inc. Heterocycles as protein kinase inhibitors
UY32049A (es) 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
JP5781510B2 (ja) * 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
EP2467383A1 (en) 2009-08-20 2012-06-27 Novartis AG Heterocyclic oxime compounds
ME02211B (me) * 2009-12-31 2016-02-20 Hutchison Medipharma Ltd Neki triazolopirazini, njihove kompozicije i postupci njihovog korišćenja
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物

Also Published As

Publication number Publication date
CY1118250T1 (el) 2017-06-28
MX336996B (es) 2016-02-09
EP3795573A1 (en) 2021-03-24
KR20170098324A (ko) 2017-08-29
DK3511330T3 (da) 2020-12-21
US10512645B2 (en) 2019-12-24
AU2010338712B2 (en) 2015-04-02
JP6486999B2 (ja) 2019-03-20
HK1194071A1 (en) 2014-10-10
EP2519524A4 (en) 2013-07-03
SI3511330T1 (sl) 2021-01-29
BR112012016129A2 (pt) 2016-05-31
CN102906092A (zh) 2013-01-30
JP5337313B2 (ja) 2013-11-06
IL239997A0 (en) 2015-08-31
AU2010338712A1 (en) 2012-07-12
UA107822C2 (en) 2015-02-25
HUE025504T2 (en) 2016-02-29
SG181781A1 (en) 2012-07-30
US10946014B2 (en) 2021-03-16
HRP20150952T1 (hr) 2015-10-09
IL220433B (en) 2018-01-31
JP2018009004A (ja) 2018-01-18
ES2927146T3 (es) 2022-11-02
KR20140059307A (ko) 2014-05-15
SMT201500213B (it) 2015-10-30
EP2719699A1 (en) 2014-04-16
CO6612235A2 (es) 2013-02-01
US20120245178A1 (en) 2012-09-27
HRP20221090T1 (hr) 2022-11-25
NZ601128A (en) 2014-12-24
PE20160588A1 (es) 2016-07-09
ES2726152T3 (es) 2019-10-02
KR101771299B1 (ko) 2017-08-24
US20120264739A1 (en) 2012-10-18
CU24167B1 (es) 2016-03-31
DOP2012000188A (es) 2012-12-31
ES2840454T3 (es) 2021-07-06
EA201200951A1 (ru) 2013-09-30
ZA201205730B (en) 2016-01-27
EA025466B1 (ru) 2016-12-30
EP2966075B1 (en) 2019-02-27
GT201200220A (es) 2014-12-22
CN106432225A (zh) 2017-02-22
JP6194046B2 (ja) 2017-09-06
US20180263977A1 (en) 2018-09-20
EA201691461A1 (ru) 2017-01-30
BR112012016129B1 (pt) 2020-11-03
AU2015203480A1 (en) 2015-07-16
LT3795573T (lt) 2022-11-10
PL2719699T3 (pl) 2016-01-29
US20210154192A1 (en) 2021-05-27
JP6647434B2 (ja) 2020-02-14
CN106117248B (zh) 2019-01-22
NI201200118A (es) 2013-01-24
PE20211094A1 (es) 2021-06-14
HUE052828T2 (hu) 2021-05-28
RS63612B1 (sr) 2022-10-31
PE20130375A1 (es) 2013-04-10
RS54217B1 (en) 2015-12-31
EP2519524A1 (en) 2012-11-07
EA030141B1 (ru) 2018-06-29
DK2719699T3 (da) 2015-08-24
HRP20202017T1 (hr) 2021-02-19
SI2719699T1 (sl) 2015-12-31
PL3511330T3 (pl) 2021-04-19
JP2019108345A (ja) 2019-07-04
PT2719699E (pt) 2015-09-30
US8507487B2 (en) 2013-08-13
JP2016155848A (ja) 2016-09-01
US9956218B2 (en) 2018-05-01
MX2012007756A (es) 2012-11-06
CL2012001752A1 (es) 2013-01-25
US20150368271A1 (en) 2015-12-24
US11896592B2 (en) 2024-02-13
EP3511330A1 (en) 2019-07-17
PT3511330T (pt) 2020-12-24
KR101434766B1 (ko) 2014-08-26
CY1123777T1 (el) 2022-03-24
CN106432225B (zh) 2019-02-19
KR101905350B1 (ko) 2018-11-30
PL3795573T3 (pl) 2022-11-21
PT3795573T (pt) 2022-09-15
ECSP12012011A (es) 2012-10-30
RS61281B1 (sr) 2021-02-26
AU2015203480B2 (en) 2017-10-26
EP3795573B1 (en) 2022-07-06
CN106117248A (zh) 2016-11-16
WO2011079804A1 (en) 2011-07-07
JP2013209418A (ja) 2013-10-10
MY179933A (en) 2020-11-19
EP2719699B1 (en) 2015-07-08
CN102906092B (zh) 2016-08-03
US8987269B2 (en) 2015-03-24
US20200179377A1 (en) 2020-06-11
US20170027934A1 (en) 2017-02-02
EP3511330B1 (en) 2020-09-30
CA2785749C (en) 2017-11-28
EP2966075A1 (en) 2016-01-13
CA2785749A1 (en) 2011-07-07
JP2013516393A (ja) 2013-05-13
KR20120125261A (ko) 2012-11-14
IL239997A (en) 2017-11-30
ES2546635T3 (es) 2015-09-25
CU20120101A7 (es) 2012-10-15
ME02211B (me) 2016-02-20
HK1216880A1 (zh) 2016-12-09
HUE059696T2 (hu) 2022-12-28

Similar Documents

Publication Publication Date Title
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
DK2419670T3 (da) Leveringsmetode og sammensætninger
DK2504353T4 (da) Lipopeptidsammensætninger og tilsvarende fremgangsmåder
DK3196309T3 (da) Thraustochytrider, fedtsyresammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK3569256T3 (da) Stabiliserede fibronectin-domænesammensætninger, fremgangsmåder og anvendelser
DK3812360T3 (da) Monochlortrifluorpropen forbindelser og sammensætninger og metoder, der anvender dem
DK2408337T3 (da) Pude, kit og fremgangsmåde til fremstilling heraf
DK3127540T3 (da) Visse amino-pyrimidiner, sammensætninger deraf, og fremgangsmåder til deres anvendelse
DK2419732T3 (da) Prionfrie nanopartikelsammensætninger og fremgangsmåder
DK2467173T3 (da) Sårbandager, fremgangsmåder til anvendelse heraf og fremgangsmåder til dannelse deraf
DK2585437T3 (da) Thioacetatforbindelser, sammensætninger og fremgangsmåder til anvendelse heraf
BR112013010725A2 (pt) método, e, composição
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2473034T3 (da) Frøbehandlingssammensætninger og fremgangsmåde
DK3128014T3 (da) Midler og fremgangsmåder til sterilisering af biofunktionelle sammensætninger
DK2245032T3 (da) Folater, sammensætninger og anvendelser deraf
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä
DK2513193T3 (da) Forbedrede blends af polyarylenethere og polyarylensulfider
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
DK2805746T3 (da) Alkylamido-forbindelser og anvendelser deraf
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
DK2415349T3 (da) Fremgangsmåde til fremstilling af afsaltet mælk, og afsaltet mælk
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK2482841T4 (da) Sammensætninger og fremgangsmåder til at forbedre koagulationsfaktor-viii-funktion
DK2552484T3 (da) Fremgangsmåder og sammensætninger til reducering af parathyroidniveauer